drugset
drugset / Trial / NCT01393964

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

NCT01393964 ↗

Phase 1 Completed 35 enrolled Bristol-Myers Squibb AbbVie · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the concentration of Elotuzumab in Myeloma patients with very low kidney function including patients on dialysis.

Timeline

Start
2012-01-06
Primary completion
2014-03-21
Completion
2016-07-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Elotuzumab Monoclonal antibody 10 mg/kg Intravenous
Background Dexamethasone Small molecule 8 mg Oral
Background Dexamethasone Small molecule 28 mg Oral
Background Dexamethasone Small molecule 40 mg Oral
Background Lenalidomide Other / unclassified 15 mg Oral

Indications

plasma cell myeloma